| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7928122 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US7745460 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US7314938 | NOVARTIS | Modulators of cellular adhesion |
Mar, 2025
(10 months from now) | |
| US8084047 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(2 years from now) | |
| US9890141 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7790743 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US10124000 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US9216174 | NOVARTIS | Modulators of cellular adhesion |
Nov, 2024
(6 months from now) | |
| US8592450 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2026
(2 years from now) | |
| US8367701 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(4 years from now) | |
| US9447077 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Apr, 2029
(4 years from now) | |
| US8168655 | NOVARTIS | Compositions and methods for treatment of eye disorders |
May, 2029
(5 years from now) | |
| US9353088 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Oct, 2030
(6 years from now) | |
| US8927574 | NOVARTIS | Crystalline pharmaceutical and methods of preparation and use thereof |
Nov, 2030
(6 years from now) | |
| US9085553 | NOVARTIS | LFA-1 inhibitor and methods of preparation and polymorph thereof |
Jul, 2033
(9 years from now) | |
| US11058677 | NOVARTIS | LFA-1 inhibitor formulations |
Dec, 2033
(9 years from now) | |
Xiidra is owned by Novartis.
Xiidra contains Lifitegrast.
Xiidra has a total of 16 drug patents out of which 0 drug patents have expired.
Xiidra was authorised for market use on 11 July, 2016.
Xiidra is available in solution/drops;ophthalmic dosage forms.
Xiidra can be used as treatment of the signs and symptoms of dry eye disease (ded), treatment of signs and symptoms of dry eye disease (ded).
Drug patent challenges can be filed against Xiidra from 11 July, 2020.
The generics of Xiidra are possible to be released after 18 December, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 11, 2021 |
Drugs and Companies using LIFITEGRAST ingredient
NCE-1 date: 11 July, 2020
Market Authorisation Date: 11 July, 2016
Treatment: Treatment of signs and symptoms of dry eye disease (ded); Treatment of the signs and symptoms of dry eye disease (ded)
Dosage: SOLUTION/DROPS;OPHTHALMIC
XIIDRA family patents
